Developing drugs for

DEMENTIA

Dementia is a group of neurodegenerative diseases leading to gradual loss of brain function –  such as memory, cognition and daily activities. Dementia is one of the largest unmet healthcare challenges of today. Pharmasum Therapeutics is developing a drug representing a unique innovation in a global market, serving an extremely high unmet medical need.

The Most Common Disease of Our Time

Worldwide, around 55 million people have dementia reaching about 150 million cases in 2050 (WHO 2023). Alzheimer’s disease is the most common form of dementia and contribute to 60–70% of cases. This is a progressive disease leading to death within 10 years. Today, significant therapy options are lacking.

Technology

Scientific approach

The drug candidate PST-674 is a proprietary inhibitor of DYRK1A, which is an enzyme involved in several important processes in the brain. An overdose/overactivity of DYRK1A leads to dementia. The inhibition of DYRK1A therefore offers a novel therapeutic approach for treatment of Alzheimer´s disease.

Patients

Clinical Approach

Pharmasum Therapeutics plans a Proof-of-Concept (PoC) clinical study in individuals with Down syndrome and dementia, where the genetic link to our drug target DYRK1A is strong, and the clinical chance of success high due to less heterogenicity compared to Alzheimer´s disease in general.

A Global Market

The dementia therapy market is projected to reach 40 billion dollars by 2030 with strong growth expected due to new therapies.
 

Market segments:

  • Alzheimer’s disease
  • Parkinson’s disease
  • Down syndrome

The value creation of the technology for society and patients is potentially vast. Pharmasum Therapeutics shares hold significant potential for value growth.

Business Strategy

Pharmasum Therapeutic´s business strategy is to enter partnership with a major pharmaceutical company for late-stage development.

About the Company

Pharmasum Therapeutics is a private Norwegian pharmaceutical company focused on the discovery and development of novel drugs for treatment of neurological diseases. Pharmasum Therapeutic´s experienced team operates from Norway, and the UK.

Investor Relations

Investor support is crucial for advancing clinical trials and bringing new therapies to market – creating value for both patients and stakeholders.

Investor Relations,
Please contact: Anders Fugelli

Skroll til toppen